EA201592203A1 - Способы лечения таупатии - Google Patents
Способы лечения таупатииInfo
- Publication number
- EA201592203A1 EA201592203A1 EA201592203A EA201592203A EA201592203A1 EA 201592203 A1 EA201592203 A1 EA 201592203A1 EA 201592203 A EA201592203 A EA 201592203A EA 201592203 A EA201592203 A EA 201592203A EA 201592203 A1 EA201592203 A1 EA 201592203A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- taupathy
- treatment
- tau
- present
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
В настоящем изобретении предусматриваются способы лечения таупатии, включающие введение антитела к Тау. В настоящем изобретении предусматриваются также антитела к Тау и композиции, содержащие их, для применения в этих способах.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361833355P | 2013-06-10 | 2013-06-10 | |
US14/092,539 US8926974B2 (en) | 2012-08-16 | 2013-11-27 | Methods of treating a tauopathy |
PCT/US2014/041553 WO2014200921A1 (en) | 2013-06-10 | 2014-06-09 | Methods of treating a tauopathy |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201592203A1 true EA201592203A1 (ru) | 2016-05-31 |
EA039554B1 EA039554B1 (ru) | 2022-02-09 |
Family
ID=52022687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201592203A EA039554B1 (ru) | 2013-06-10 | 2014-06-09 | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP3007726B1 (ru) |
JP (1) | JP6446443B2 (ru) |
CN (1) | CN105339002B (ru) |
BR (1) | BR112015030356A2 (ru) |
CA (2) | CA2914768A1 (ru) |
CY (1) | CY1123672T1 (ru) |
DK (1) | DK3007726T3 (ru) |
EA (1) | EA039554B1 (ru) |
ES (1) | ES2800827T3 (ru) |
HR (1) | HRP20201064T1 (ru) |
HU (1) | HUE050485T2 (ru) |
LT (1) | LT3007726T (ru) |
MX (2) | MX370723B (ru) |
PL (1) | PL3007726T3 (ru) |
PT (1) | PT3007726T (ru) |
RS (1) | RS60883B1 (ru) |
SI (1) | SI3007726T1 (ru) |
WO (1) | WO2014200921A1 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20150646A1 (es) | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
JO3576B1 (ar) | 2015-02-26 | 2020-07-05 | Lilly Co Eli | أجسام مضادة لـ tau واستخداماتها |
AR104875A1 (es) | 2015-06-05 | 2017-08-23 | Genentech Inc | Anticuerpos anti-tau y métodos de uso |
EP3496750A2 (en) | 2016-08-09 | 2019-06-19 | Eli Lilly and Company | Combination therapy |
AR110321A1 (es) * | 2016-12-07 | 2019-03-20 | Genentech Inc | Anticuerpos antitau y métodos de uso |
AU2017373884A1 (en) | 2016-12-07 | 2019-05-30 | Ac Immune Sa | Anti-tau antibodies and methods of their use |
JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
EA202090063A1 (ru) * | 2017-06-16 | 2020-04-03 | Бристоль-Мейерз Сквибб Компани | Композиции и способы для лечения таупатий |
JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
CN112543648A (zh) | 2018-07-31 | 2021-03-23 | 伊莱利利公司 | 组合疗法 |
JP2022043373A (ja) * | 2018-12-28 | 2022-03-16 | 国立大学法人京都大学 | 大脳皮質細胞からのl1cam陽性細胞の取得およびその細胞製剤としての使用 |
US20220177558A1 (en) * | 2019-03-25 | 2022-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Treatment of taupathy disorders by targeting new tau species |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5811310A (en) * | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US6010913A (en) | 1992-12-14 | 2000-01-04 | N.V. Innogenetics S.A. | Isolated human tau peptide |
US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
ES2328585T3 (es) | 1993-10-25 | 2009-11-16 | Canji, Inc. | Vector de adenovirus recombinante y metodo de utilizacion. |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
JP3522285B2 (ja) | 1994-12-09 | 2004-04-26 | インペリアル カレッジ イノベイションズ リミテッド | 遺伝子の同定 |
WO1996019487A1 (fr) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Derives d'organobismuth et procede de production |
US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
US5968738A (en) | 1995-12-06 | 1999-10-19 | The Board Of Trustees Of The Leland Stanford Junior University | Two-reporter FACS analysis of mammalian cells using green fluorescent proteins |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
DK0939647T4 (da) | 1996-08-27 | 2006-10-23 | Novartis Vaccines & Diagnostic | Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
TW371617B (en) | 1996-10-09 | 1999-10-11 | Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau | Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
AU741166B2 (en) | 1997-12-12 | 2001-11-22 | Macromed, Inc. | Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification |
US5985577A (en) | 1998-10-14 | 1999-11-16 | The Trustees Of Columbia University In The City Of New York | Protein conjugates containing multimers of green fluorescent protein |
BR0107851A (pt) | 2000-01-24 | 2002-10-29 | Innogenetics Nv | Diagnose de tauopatia |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
DK1427709T3 (da) | 2001-09-21 | 2006-04-03 | Mitsubishi Pharma Corp | 3-substituerede 4-pyrimidonderivater |
JP2008503217A (ja) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | 新規抗原結合ポリペプチド及びそれらの使用 |
US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
WO2010063124A1 (en) | 2008-12-05 | 2010-06-10 | Angiochem Inc. | Peptide therapeutic conjugates and uses thereof |
US9605054B2 (en) * | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
US20130295021A1 (en) * | 2010-10-11 | 2013-11-07 | Feng Chen | Human anti-tau antibodies |
US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
PE20150646A1 (es) * | 2012-08-16 | 2015-05-21 | Ipierian Inc | Metodos de tratamiento de una tauopatia |
US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
-
2014
- 2014-06-09 CN CN201480032717.2A patent/CN105339002B/zh active Active
- 2014-06-09 LT LTEP14734364.4T patent/LT3007726T/lt unknown
- 2014-06-09 WO PCT/US2014/041553 patent/WO2014200921A1/en active Application Filing
- 2014-06-09 BR BR112015030356A patent/BR112015030356A2/pt active Search and Examination
- 2014-06-09 CA CA2914768A patent/CA2914768A1/en not_active Abandoned
- 2014-06-09 EP EP14734364.4A patent/EP3007726B1/en active Active
- 2014-06-09 ES ES14734364T patent/ES2800827T3/es active Active
- 2014-06-09 SI SI201431606T patent/SI3007726T1/sl unknown
- 2014-06-09 RS RS20200796A patent/RS60883B1/sr unknown
- 2014-06-09 MX MX2015016240A patent/MX370723B/es active IP Right Grant
- 2014-06-09 DK DK14734364.4T patent/DK3007726T3/da active
- 2014-06-09 EA EA201592203A patent/EA039554B1/ru unknown
- 2014-06-09 JP JP2016519574A patent/JP6446443B2/ja not_active Expired - Fee Related
- 2014-06-09 HU HUE14734364A patent/HUE050485T2/hu unknown
- 2014-06-09 EP EP20162335.2A patent/EP3760228A1/en active Pending
- 2014-06-09 CA CA3173775A patent/CA3173775A1/en active Pending
- 2014-06-09 PT PT147343644T patent/PT3007726T/pt unknown
- 2014-06-09 PL PL14734364T patent/PL3007726T3/pl unknown
-
2015
- 2015-11-25 MX MX2019015604A patent/MX2019015604A/es unknown
-
2020
- 2020-07-03 CY CY20201100614T patent/CY1123672T1/el unknown
- 2020-07-07 HR HRP20201064TT patent/HRP20201064T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014200921A1 (en) | 2014-12-18 |
EP3007726A1 (en) | 2016-04-20 |
CA3173775A1 (en) | 2014-12-18 |
HUE050485T2 (hu) | 2020-12-28 |
DK3007726T3 (da) | 2020-07-06 |
EP3007726B1 (en) | 2020-04-08 |
HRP20201064T1 (hr) | 2021-01-22 |
MX2015016240A (es) | 2016-08-11 |
CY1123672T1 (el) | 2022-03-24 |
EP3760228A1 (en) | 2021-01-06 |
MX370723B (es) | 2019-12-20 |
MX2019015604A (es) | 2020-02-26 |
JP6446443B2 (ja) | 2018-12-26 |
EA039554B1 (ru) | 2022-02-09 |
BR112015030356A2 (pt) | 2017-12-05 |
SI3007726T1 (sl) | 2020-11-30 |
CN105339002A (zh) | 2016-02-17 |
LT3007726T (lt) | 2020-09-10 |
CN105339002B (zh) | 2019-06-28 |
JP2016525502A (ja) | 2016-08-25 |
PT3007726T (pt) | 2020-06-22 |
PL3007726T3 (pl) | 2021-01-11 |
RS60883B1 (sr) | 2020-11-30 |
ES2800827T3 (es) | 2021-01-04 |
CA2914768A1 (en) | 2014-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201592203A1 (ru) | Способы лечения таупатии | |
EA201590388A1 (ru) | Способы лечения таупатии | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
CY1120035T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
EA201790413A1 (ru) | Антитела против tigit | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
EA201790248A1 (ru) | Композиции носитель-антитело и способы их получения и применения | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201600473A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
EA201592213A1 (ru) | Антитела антирецептор трансферрина и способы их использования | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
EA201691266A1 (ru) | Анти-cd3 антитела и способы применения | |
EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
EA201792348A1 (ru) | Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии | |
EA202090547A3 (ru) | Макроциклические деаза-оксипурины для лечения вирусных инфекций | |
EA201591740A1 (ru) | Вирусы болезни ньюкасла и их применение | |
EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения |